Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Says FDA Clears Two U.S. Drug Facilities Of GMP Violations

This article was originally published in PharmAsia News

Executive Summary

Sun Pharmaceutical said its Caraco Pharmaceutical Laboratories unit in the U.S. has been returned to compliance with good manufacturing practices, having fixed problems that led to U.S. FDA action in 2009.

You may also be interested in...



Vindevogel’s Vision Healthcare Secures Avista Backing For US Entry

New York's Avista Capital Partners has taken a 50% stake in Belgian consumer health player Vision Healthcare, which has its sights set on the US market.

Sun Sees New Prescriptions Drought Amid COVID-19

Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.

Fact File: European COVID-19 Focus Shifts To Managing The ‘New Normal’

The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.

Topics

UsernamePublicRestriction

Register

PS142283

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel